MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies

Bu-Fu Tang; Wang-Ting Xu; Shi-Ji Fang; Jin-Yu Zhu; Rong-Fang Qiu; Lin Shen; Yang Yang; Qiao-You Weng; Ya-Jie Wang; Jia-Yi Ding; Xiao-Jie Zhang; Wei-Qian Chen; Li-Yun Zheng; Jing-Jing Song; Biao Chen; Zhong-Wei Zhao; Min-Jiang Chen; Jian-Song Ji

doi:10.1186/s40779-024-00588-7

Your Location：

Home >

Browse articles >

MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies

RESEARCH | Updated：2025-12-13

- MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies
- MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies
- “在癌症治疗领域，研究人员取得了重大进展。他们发现射频消融（RFA）治疗上调了MELK的表达，MELK抑制通过免疫原性细胞死亡和抗肿瘤反应促进了RFA的疗效。通过RGD-LNPs靶向MELK为提高RFA在HCC临床治疗和对抗癌症恶性进展中的疗效提供了新的见解。”
- MMR 2025年12卷第7期页码：1046-1064
- Affiliations：
  
  1.Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Lishui Hospital, School of Medicine, Zhejiang University, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, Zhejiang, China
  2.Institute of Imaging Diagnosis and Minimally Invasive Intervention Research, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, Zhejiang, China
  3.Department of Radiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China
  4.Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China
  5.Clinical College of the Affiliated Central Hospital, School of Medicine, Lishui University, Lishui 323000, Zhejiang, China
- Author bio：
  
  * zhaozw79@163.com
  minjiangchen@wmu.edu.cn
  jijiansong@zju.edu.cn
- Funds：
  
  the National Natural Science Foundation of China(82072025;82072026;82102162;82303886);the "Leading Goose" Research and Development Program of Zhejiang Province(2023C03062);the National Natural Science Foundation of Zhejiang Province(LY22H160040;LQ22H180010);the Key Research and Development Project of Lishui City(2022ZDYF12;2022ZDYF20;2022ZDYF20)
- DOI：10.1186/s40779-024-00588-7
  中图分类号：
- 纸质出版：2025-07
- Accepted：
Scan QR Code
MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies[J]. MMR, 2025,12(7):1046-1064.

Cite this article as: Tang BF, Xu WT, Fang SJ, Zhu JY, Qiu RF, Shen L, et al. MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies. Mil Med Res. 2025;12(1):5.
MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies[J]. MMR, 2025,12(7):1046-1064. DOI： 10.1186/s40779-024-00588-7.

Cite this article as: Tang BF, Xu WT, Fang SJ, Zhu JY, Qiu RF, Shen L, et al. MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies. Mil Med Res. 2025;12(1):5. DOI： 10.1186/s40779-024-00588-7.

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Role of the immune microenvironment in bone, cartilage, and soft tissue regeneration: from mechanism to therapeutic opportunity

mRNA vaccine development for cholangiocarcinoma: a precise pipeline

基于ANSYS的EP电磁阀静态性能仿真分析

杭州湾大桥梁上运梁过程仿真分析

既有线钢桁梁桥横向刚度加固技术

MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies

MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies

DOI：10.1186/s40779-024-00588-7